Vistagen Therapeutics (VTGN) EBT (2011 - 2026)

Vistagen Therapeutics has disclosed EBT across 15 years of filings, most recently posting -$13.0 million for Q2 2026.

• In Q2 2026, EBT rose 13.68% year-over-year to -$13.0 million; the TTM figure through Jun 2026 stood at -$67.6 million (down 21.27% YoY), while the FY2026 annual figure was -$69.7 million, down 35.57% from the prior year.
• EBT came in at -$13.0 million for Q2 2026 at Vistagen Therapeutics, up from -$16.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$6.4 million in Q4 2023 to a low of -$19.8 million in Q2 2022.
• Average EBT over 5 years is -$13.3 million, with a median of -$13.3 million recorded in 2025.
• Year-over-year, EBT plunged 168.68% in 2022 and surged 65.1% in 2023.
• Over 5 years, EBT stood at -$9.8 million in 2022, then surged by 34.95% to -$6.4 million in 2023, then tumbled by 121.87% to -$14.1 million in 2024, then plunged by 34.14% to -$18.9 million in 2025, then soared by 31.05% to -$13.0 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$13.0 million in Q2 2026, -$16.3 million in Q1 2026, and -$18.9 million in Q4 2025.